The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-analysis of RCTs
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Hypnotics have a role in the management of acute insomnia; however, the efficacy and safety of pharmacological interventions in the management of chronic insomnia is unclear.
The objective of this paper is to conduct a systematic review of the efficacy and safety of drug treatments for chronic insomnia in adults.
Twenty-one electronic databases were searched, up to July 2006.
Randomized double-blind, placebo-controlled trials were eligible. Quality was assessed using the Jadad scale. Data were pooled using the random effects model.
One hundred and five studies were included in the review. Sleep onset latency, as measured by polysomnography, was significantly decreased for benzodiazepines (BDZ), (weighted mean difference: −10.0 minutes; 95% CI: −16.6, −3.4), non-benzodiazepines (non-BDZ) (−12.8 minutes; 95% CI: −16.9, −8.8) and antidepressants (ADP) (−7.0 minutes; 95% CI: −10.7, −3.3). Sleep onset latency assessed by sleep diaries was also improved (BDZ: −19.6 minutes; 95% CI: −23.9, −15.3; non-BDZ: −17.0 minutes; 95% CI: −20.0, −14.0; ADP: −12.2 minutes; 95% CI: −22.3, −2.2). Indirect comparisons between drug categories suggest BDZ and non-BDZ have a similar effect. All drug groups had a statistically significant higher risk of harm compared to placebo (BDZ: risk difference [RD]: 0.15; non-BDZ RD: 0.07; and ADP RD: 0.09), although the most commonly reported adverse events were minor. Indirect comparisons suggest that non-BDZ are safer than BDZ.
Benzodiazepines and non-benzodiazepines are effective treatments in the management of chronic insomnia, although they pose a risk of harm. There is also some evidence that antidepressants are effective and that they pose a risk of harm.
- Sateia MJ, Doghramji K, Hauri P, Morin CM. Evaluation of chronic insomnia. An American Academy of Sleep Medicine Review. Sleep 2000;23:1–66.
- Ford D, Kamerow D. Epidemiological study of sleep disturbances and psychiatric disorders: an opportunity for prevention. JAMA 1989;262:1479–84. CrossRef
- Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry. 1997;54:1417–23.
- Leger D, Guilleminault C, Bader G, Levy E, Paillard M. Medical and socio-professional impact of insomnia. Sleep 2002;25:625–9.
- Ohayon M. Epidemiological study on insomnia in the general population. Sleep 1996;19(3 suppl):S7–15.
- Roberts RE, Shema SJ, Kaplan GA. Prospective data on sleep complaints and associated risk factors in an older cohort. Psychosom Med. 1999;61:188–96.
- Foley DJ, Monjan A, Simonsick EM, Wallace RB, Blazer DG. Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years. Sleep 1999;22(suppl 2):S366–72.
- Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbances and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry. 1996;39:411–18. CrossRef
- Wiessman MM, Greenwald A, NinoMurcia G, Dement WC. The morbidity of insomnia uncomplicated by psychiatric disorders. Gen Hosp Psychiatry. 1997;19:245–50. CrossRef
- NIH 1983. Drugs and Insomnia: The Use of Medications To Promote Sleep. NIH Consens Statement Online 1983 Nov 5–17 [cited 2005 08 29];4(10):1–19.
- NIH 1990. The Treatment of Sleep Disorders of Older People. NIH Consens Statement Online 1990 Mar 26–28 [cited 2005 08 29];8(3):1–22.
- Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: meta-analysis of treatment efficacy. J Am Med Assoc. 1997;278:2170–7. CrossRef
- Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. Can Med Assoc J. 2000;162:225–33.
- Smith MT, Perlis ML, Park A, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002;159:5–11. CrossRef
- Glass J, Lanctot K, Hermmnn N, Sproule BA, Busto U. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005;331:1169. CrossRef
- Dunbar Y, Dodd S, Strobl J, Boland A, Dickson R, Wally T. Comparative efficacy of newer hypnotic agents for the short-term management of insomnia: a systematic review and meta-analysis. Human Psychopharmacol Clin Exp. 2004;19:305–322. CrossRef
- Buscemi N, Vandermeer B, Friesen C, et al. Manifestations and management of chronic insomnia in adults. Evid Rep Technol Assess (Summ). 2005 Jun;(125):1–10.
- Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. CrossRef
- Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Am Med Assoc. 1995;273:408–12. CrossRef
- Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58. CrossRef
- Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Eggar M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in context. 3rd ed. London: BMJ Publishing Group; 2001:285–312.
- Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683–691. CrossRef
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101. CrossRef
- Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315:629–34.
- Duval S, Tweedie R. A nonparametric “tim and fill” method of accounting for publication bias in meta-analysis. J Am Med Assoc. 2000;95:89–98.
- Light RJ, Pillemer DB. Summing up. The science of reviewing research. Cambridge, MA: Harvard University Press; 1984.
- Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep 1999;22(3):371–5.
- Panneman MJ, Goettsch WG, Kramarz P, Herings RM. The costs of benzodiazepine-associated hospital-treated fall Injuries in the EU: a Pharmo study. Drugs Aging. 2003;20:833–9. CrossRef
- Soldatos CR, Dikeos DG, Whiehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol. 1999;14(5):287–303.
- The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-analysis of RCTs
Journal of General Internal Medicine
Volume 22, Issue 9 , pp 1335-1350
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. University of Alberta/Capital Health Evidence-Based Practice Centre, Department of Pediatrics, University of Alberta, Alberta, Canada
- 3. Aberhart Centre One, Room 9428, 11402 University Avenue, Edmonton, AB, T6J 2G3, Canada
- 2. Department of Pediatrics, University of Alberta, Alberta, Canada